MedTrace Logo

Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma

NCT04205357 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-03-03

No results posted yet for this study

Summary

This study evaluates the safety associated with the addition of sulfasalazine to stereotactic radiosurgery for recurrent glioblastoma. Sulfasalazine is a potential tumor selective radiosensitizer.

Conditions

Interventions

DRUG

Sulfasalazine

Sulfasalazine combined with stereotactic radiosurgery

Sponsors & Collaborators

  • Norwegian Cancer Society

    collaborator OTHER

  • Northwell Health

    collaborator OTHER

  • Weill Medical College of Cornell University

    collaborator OTHER

  • University of Bergen

    collaborator OTHER

  • Helse Stavanger HF

    collaborator OTHER_GOV

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Bente S Skeie · Haukeland University Hospial

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2022-10-14
Completion
2022-10-14

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04205357 on ClinicalTrials.gov